{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:38:19Z","timestamp":1777631899377,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["428857858"],"award-info":[{"award-number":["428857858"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU344"],"award-info":[{"award-number":["CRU344"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.beha.2021.101282","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T12:27:00Z","timestamp":1625142420000},"page":"101282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of telomeropathies"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-4522","authenticated-orcid":false,"given":"Margherita","family":"Vieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.beha.2021.101282_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0301-472X(02)00888-3","article-title":"Longitudinal studies of telomere length in feline blood cells: implications for hematopoietic stem cell turnover in vivo","volume":"30","author":"Brummendorf","year":"2002","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101282_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nbt0898-743","article-title":"Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry","volume":"16","author":"Rufer","year":"1998","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc3025","article-title":"Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins","volume":"11","author":"Martinez","year":"2011","journal-title":"Nat Rev Canc"},{"issue":"10","key":"10.1016\/j.beha.2021.101282_bib4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/sj.leu.2404339","article-title":"Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover","volume":"20","author":"Brummendorf","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2021.101282_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/asheducation-2011.1.480","article-title":"Dyskeratosis congenita","volume":"2011","author":"Dokal","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"10.1016\/j.beha.2021.101282_bib6","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1073\/pnas.0800042105","article-title":"Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita","volume":"105","author":"Vulliamy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.beha.2021.101282_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/hmg\/ddm111","article-title":"Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10","volume":"16","author":"Walne","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1172\/JCI78963","article-title":"Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita","volume":"125","author":"Tummala","year":"2015","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00439-013-1265-8","article-title":"Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita","volume":"132","author":"Ballew","year":"2013","journal-title":"Hum Genet"},{"issue":"36","key":"10.1016\/j.beha.2021.101282_bib10","doi-asserted-by":"crossref","first-page":"E3408","DOI":"10.1073\/pnas.1300600110","article-title":"Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome","volume":"110","author":"Deng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ng.1084","article-title":"Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus","volume":"44","author":"Anderson","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1101\/gad.2006411","article-title":"Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita","volume":"25","author":"Zhong","year":"2011","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2014-06-566810","article-title":"Bone marrow skeletal stem\/progenitor cell defects in dyskeratosis congenita and telomere biology disorders","volume":"125","author":"Balakumaran","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2021.101282_bib14","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.1504780112","article-title":"Telomere dysfunction causes alveolar stem cell failure","volume":"112","author":"Alder","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.13442","article-title":"Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder","volume":"170","author":"Glousker","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ajhg.2012.02.002","article-title":"Mutations in CTC1, encoding the CTS telomere maintenance complex component 1, cause cerebroretinal microangiopathy with calcifications and cysts","volume":"90","author":"Polvi","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13023-020-01553-y","article-title":"Revesz syndrome revisited","volume":"15","author":"Karremann","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beha.2021.101282_bib18","first-page":"157","article-title":"The diagnosis and treatment of dyskeratosis congenita: a review","volume":"5","author":"Fernandez Garcia","year":"2014","journal-title":"Hematol Res Rev"},{"issue":"26","key":"10.1016\/j.beha.2021.101282_bib19","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1182\/blood-2008-12-192880","article-title":"Cancer in dyskeratosis congenita","volume":"113","author":"Alter","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101282_bib20","first-page":"845125","article-title":"Dyskeratosis congenita: a report of two cases","volume":"2013","author":"Karunakaran","year":"2013","journal-title":"Case Rep Dent"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13148-020-00914-5","article-title":"PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation","volume":"12","author":"Cypris","year":"2020","journal-title":"Clin Epigenet"},{"issue":"10","key":"10.1016\/j.beha.2021.101282_bib22","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.18632\/oncotarget.7458","article-title":"DNA methylation in PRDM8 is indicative for dyskeratosis congenita","volume":"7","author":"Weidner","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beha.2021.101282_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.190.2.157","article-title":"Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood","volume":"190","author":"Rufer","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/nyas.14248","article-title":"Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies","volume":"1466","author":"Ferreira","year":"2020","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.blre.2010.03.002","article-title":"Pathophysiology and management of inherited bone marrow failure syndromes","volume":"24","author":"Shimamura","year":"2010","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.beha.2021.101282_bib27","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1183\/13993003.00308-2016","article-title":"Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive","volume":"48","author":"Newton","year":"2016","journal-title":"Eur Respir J"},{"issue":"9396","key":"10.1016\/j.beha.2021.101282_bib28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0140-6736(03)14797-6","article-title":"Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA","volume":"362","author":"Fogarty","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2021.101282_bib29","series-title":"Dyskeratosis congenita and telomere biology disorders: diagnosis and management guidelines","author":"Savage","year":"2015"},{"key":"10.1016\/j.beha.2021.101282_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/978-90-481-9485-8_28","article-title":"Advocacy groups and their role in rare diseases research","volume":"686","author":"Dunkle","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"18","key":"10.1016\/j.beha.2021.101282_bib31","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2014-05-526285","article-title":"Bone marrow failure and the telomeropathies","volume":"124","author":"Townsley","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101282_bib32","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bbmt.2013.05.021","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita","volume":"19","author":"Gadalla","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/bmt.2010.65","article-title":"Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita","volume":"46","author":"Dietz","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.15495","article-title":"Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita","volume":"183","author":"Fioredda","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2021.101282_bib35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2016.03.001","article-title":"Survival after hematopoietic stem cell transplant in patients with dyskeratosis congenita: systematic review of the literature","volume":"22","author":"Barbaro","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2017.1.88","article-title":"Inherited bone marrow failure syndromes: considerations pre- and posttransplant","volume":"2017","author":"Alter","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.01.075","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2016.1.90","article-title":"Transplantation for bone marrow failure: current issues","volume":"2016","author":"Peffault de Latour","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2021.101282_bib39","series-title":"Hematopoietic cell transplantation without radiation or DNA alkylating agents in bone marrow failure with short telomeres. Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR","author":"Agarwal","year":"2019"},{"key":"10.1016\/j.beha.2021.101282_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2010.1.237","article-title":"Comorbidities and hematopoietic cell transplantation outcomes","volume":"2010","author":"Sorror","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.beha.2021.101282_bib41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2141.2002.03835_2.x","article-title":"Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen","volume":"119","author":"Nobili","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000318721","article-title":"Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita","volume":"124","author":"Vuong","year":"2010","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.beha.2021.101282_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137390","article-title":"Assessing the influence of different comorbidities indexes on the outcomes of allogeneic hematopoietic stem cell transplantation in a developing country","volume":"10","author":"Teixeira","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.beha.2021.101282_bib44","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2008-09-178871","article-title":"Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells","volume":"114","author":"Calado","year":"2009","journal-title":"Blood"},{"issue":"2 Pt 1","key":"10.1016\/j.beha.2021.101282_bib45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ju.0000074653.22766.c8","article-title":"In vivo regulation of hTERT expression and telomerase activity by androgen","volume":"170","author":"Guo","year":"2003","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.beha.2021.101282_bib46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-012-1454-x","article-title":"Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation","volume":"91","author":"Ziegler","year":"2012","journal-title":"Ann Hematol"},{"issue":"20","key":"10.1016\/j.beha.2021.101282_bib47","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.16997","article-title":"Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita","volume":"193","author":"Kirschner","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bjh.12748","article-title":"Response to androgen therapy in patients with dyskeratosis congenita","volume":"165","author":"Khincha","year":"2014","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2021.101282_bib50","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2019-130844","article-title":"Telomere elongation and clinical improvement in telomeropathy patients: a prospective clinical trial of nandrolone in telomeropathies","volume":"134","author":"Cl\u00e9","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib51","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjh.16445","article-title":"Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry","volume":"189","author":"Catala","year":"2020","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.beha.2021.101282_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197196","article-title":"Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita","volume":"21","author":"Vieri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.20183","article-title":"Androgens and liver tumors: fanconi's anemia and non-Fanconi's conditions","volume":"77","author":"Velazquez","year":"2004","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2017.1.96","article-title":"Treatment of inherited bone marrow failure syndromes beyond transplantation","volume":"2017","author":"Calado","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib55","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00002030-200303280-00008","article-title":"Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting","volume":"17","author":"Hengge","year":"2003","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.beha.2021.101282_bib56","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMc1607752","article-title":"Danazol treatment for telomere diseases","volume":"375","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101282_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bcmd.2011.11.006","article-title":"Treatment of the bone marrow failure in Fanconi anemia patients with danazol","volume":"48","author":"Scheckenbach","year":"2012","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"10.1016\/j.beha.2021.101282_bib58","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/bloodadvances.2018016964","article-title":"Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita","volume":"2","author":"Khincha","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1532\/IJH97.06030","article-title":"Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita","volume":"83","author":"Al-Rahawan","year":"2006","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2021.101282_bib60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH12-02-0121","article-title":"Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia","volume":"108","author":"Trautmann","year":"2012","journal-title":"Thromb Haemostasis"},{"issue":"6","key":"10.1016\/j.beha.2021.101282_bib61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2141.2007.06718.x","article-title":"Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor","volume":"138","author":"Giri","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002460010120","article-title":"Multiple intrapulmonary arteriovenous fistulas in childhood","volume":"21","author":"Sands","year":"2000","journal-title":"Pediatr Cardiol"},{"issue":"21","key":"10.1016\/j.beha.2021.101282_bib63","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/blood-2010-11-322149","article-title":"Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase","volume":"117","author":"Parry","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101282_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2326-11-3","article-title":"Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: case Report and systematic literature review","volume":"11","author":"Giri","year":"2011","journal-title":"BMC Blood Disord"},{"issue":"5","key":"10.1016\/j.beha.2021.101282_bib65","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bmt.2016.353","article-title":"Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibroblasts","volume":"52","author":"Sorge","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib66","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1183\/09031936.00060014","article-title":"Lung transplantation in telomerase mutation carriers with pulmonary fibrosis","volume":"44","author":"Silhan","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.healun.2014.11.010","article-title":"Severe hematologic complications after lung transplantation in patients with telomerase complex mutations","volume":"34","author":"Borie","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.beha.2021.101282_bib68","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.healun.2015.05.002","article-title":"Clinical outcomes of lung transplant recipients with telomerase mutations","volume":"34","author":"Tokman","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.beha.2021.101282_bib69","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/17474086.2019.1662720","article-title":"An update on the biology and management of dyskeratosis congenita and related telomere biology disorders","volume":"12","author":"Niewisch","year":"2019","journal-title":"Expet Rev Hematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101282_bib70","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.healun.2017.02.005","article-title":"Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival","volume":"36","author":"Newton","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.beha.2021.101282_bib71","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/thoraxjnl-2016-209897","article-title":"Short lung transplant donor telomere length is associated with decreased CLAD-free survival","volume":"72","author":"Faust","year":"2017","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01875-2017","article-title":"Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation","volume":"51","author":"Justet","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.beha.2021.101282_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.607","article-title":"Successful treatment of telomeropathy-related interstitial lung disease with immunosuppression and danazol","volume":"8","author":"Chambers","year":"2020","journal-title":"Respirol Case Rep"},{"issue":"11","key":"10.1016\/j.beha.2021.101282_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007926","article-title":"A spectrum of severe familial liver disorders associate with telomerase mutations","volume":"4","author":"Calado","year":"2009","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.beha.2021.101282_bib75","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/hep.30578","article-title":"The spectrum of hepatic involvement in patients with telomere disease","volume":"69","author":"Kapuria","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib76","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jceh.2015.10.003","article-title":"Liver transplantation after bone marrow transplantation for end stage liver disease with severe hepatopulmonary syndrome in dyskeratosis congenita: a literature first","volume":"5","author":"Mahansaria","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.beha.2021.101282_bib77","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.stem.2020.03.016","article-title":"Small-Molecule PAPD5 inhibitors restore telomerase activity in patient stem cells","volume":"26","author":"Nagpal","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.beha.2021.101282_bib78","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1172\/JCI87547","article-title":"Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease","volume":"126","author":"Boyraz","year":"2016","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","article-title":"A novel orally available small molecule that inhibits hepatitis B virus expression","volume":"68","author":"Mueller","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.beha.2021.101282_bib80","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1474-9726.2011.00674.x","article-title":"Accelerated hematopoietic stem cell aging in a mouse model of dyskeratosis congenita responds to antioxidant treatment","volume":"10","author":"Gu","year":"2011","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib81","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1440-1843.2012.02132.x","article-title":"Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis","volume":"17","author":"Homma","year":"2012","journal-title":"Respirology"},{"issue":"14","key":"10.1016\/j.beha.2021.101282_bib82","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2015-08-667485","article-title":"Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia","volume":"127","author":"Bar","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101282_bib83","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.vaccine.2013.11.048","article-title":"Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes","volume":"32","author":"Alter","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.beha.2021.101282_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2014.170","article-title":"Clinical utility gene card for: dyskeratosis congenita - update 2015","volume":"23","author":"Dokal","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.beha.2021.101282_bib85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2009.08.023","article-title":"Ocular and orbital manifestations of the inherited bone marrow failure syndromes: fanconi anemia and dyskeratosis congenita","volume":"117","author":"Tsilou","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.beha.2021.101282_bib86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.seminhematol.2011.10.010","article-title":"Endocrine complications in long-term survivors after allogeneic stem cell transplant","volume":"49","author":"Gunasekaran","year":"2012","journal-title":"Semin Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:45Z","timestamp":1761498405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1521692621000475"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101282","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of telomeropathies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101282"}}